Frog Bacteria Obliterates Cancer Tumors in Single Dose

Nature keeps surprising us with its hidden pharmacies. Japanese scientists just discovered that a bacteria living in the gut of a tree frog can do something modern cancer medicine has struggled with for decades: completely eliminate tumors with a single treatment.

Led by Professor Eijiro Miyako at Japan’s Advanced Institute of Science and Technology, the research team isolated 45 bacterial strains from the intestines of Japanese tree frogs (Ewingella americana), fire belly newts, and grass lizards. After screening these candidates, nine showed anti-tumor potential. But one stood out dramatically: E. americana achieved a 100% complete response rate in mice with colorectal cancer—a result that outperformed current standard therapies like immune checkpoint inhibitors and chemotherapy.

Here’s what makes this remarkable: it’s a different approach entirely. While most gut microbiota cancer research focuses on indirect immune support, this team cultured a single bacterial strain and administered it directly via intravenous injection to attack tumors head-on. The bacteria didn’t just kill cancer cells; it activated the animal’s immune system for what the researchers called“comprehensive tumor destruction.”One dose. Complete elimination.

The safety profile is equally impressive. E. americana cleared from the bloodstream rapidly (half-life around 1.2 hours, completely gone by 24 hours), didn’t colonize any vital organs, triggered only mild temporary inflammation that normalized within three days, and showed zero chronic toxicity during a 60-day extended observation. This isn’t a miracle cure with dangerous side effects—it’s a clean, efficient therapeutic hit.

What’s particularly significant is what this signals: the gut microbiomes of lower vertebrates, largely unexplored until now, may harbor numerous uncharacterized bacterial species with exceptional therapeutic potential. As the authors noted, their findings underscore the critical importance of microbial biodiversity in advancing cancer treatment strategies. We’re not just looking at one promising bacteria. We’re looking at an untapped frontier. The question becomes not whether this approach works, but how many other organisms in nature are waiting to teach us something we desperately need to know.